ClinicalTrials.gg
TerminatedNCT05047185HAE CHAPTER-1Updated Aug 17, 2026Results posted

Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II

A Phase 2 interventional study of Deucrictibant low dose and Deucrictibant high dose in Hereditary Angioedema, Hereditary Angioedema Type I and Hereditary Angioedema Type II, sponsored by Pharvaris Netherlands B.V.. Terminated at 19 sites in 9 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by Pharvaris Netherlands B.V. · Phase 2, Interventional, and Prevention

Why this study was terminated
Sponsor decision. All remaining participants (21 total) were rolled over from Part 2 to study PHA022121-C307 (NCT06679881).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies in Angioedemas, Hereditary with a site in United Kingdom — 9 open to participants now, 16 under way, 11 of them phase 3. Angioedemas, Hereditary · United Kingdom.

Enrollment
35th of 43
34 · median 90
Started
2022
with 7 others
Phase 2
7 of 51
none open now
Registered
25th of 51
by date
Lead sponsor
7 of 51
Pharvaris Netherlands B.V.

Among the 51 studies in Angioedemas, Hereditary with a site in United Kingdom, this one is the 35th largest by enrollment of the 43 interventional ones that give a count, is one of 8 that started in 2022, is one of 7 in phase 2, and was the 25th registered.

Angioedemas, Hereditary

171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.

Browse Angioedemas, Hereditary studies →

Open to participants now

9 of the 51 studies in Angioedemas, Hereditary with a site in United Kingdom are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Angioedemas, Hereditary with a site in United Kingdom, or all of them as a file.
02

Study summary

This study evaluates the safety and efficacy of PHA-022121 administered orally for prophylaxis against angioedema attacks in patients with hereditary angioedema (HAE). The study consists of 2 parts, with patients completing participation in Part 1 prior to initiation of treatment in Part 2. Part 1 of the study has 3 parallel arms and approximately 30 patients will be equally randomized to one of two dose regimens of PHA-022121 or matching placebo. Patients will continue to the single open-label arm in Part 2 of the study after completion of Part 1. The screening period is up to 8 weeks and the treatment periods are 12 weeks (Part 1) and 30 months (Part 2) in duration.

03

Conditions studied

  • Hereditary Angioedema
  • Hereditary Angioedema Type I
  • Hereditary Angioedema Type II
  • Hereditary Angioedema Types I and II
  • Hereditary Angioedema Attack
  • Hereditary Angioedema With C1 Esterase Inhibitor Deficiency
  • Hereditary Angioedema - Type 1
  • Hereditary Angioedema - Type 2
  • C1 Esterase Inhibitor Deficiency
  • C1 Inhibitor Deficiency

Keywords

  • HAE
  • HAE Type I
  • HAE Type II
  • Oral Treatment
  • Bradykinin B2 Receptor Antagonist
  • PHVS416
  • PHA121
  • Prophylaxis
  • Deucrictibant
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed and dated form
  • Diagnosis of HAE type I or II
  • Documented history of at least 3 HAE attacks within the last 3 consecutive months prior to screening, or a minimum of 2 HAE attacks during the screening period
  • Reliable access and experience to use standard of care acute attack medications

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or breast-feeding
  • abnormal
  • Any other systemic disease or significant disease or disorder that would interfere with the patient's safety or ability to participate in the study
  • Use of C1-esterase inhibitor, oral kallikrein inhibitors, attenuated androgens, anti-fibrinolytics, or monoclonal HAE therapy within a defined period prior to enrolment
  • Abnormal hepatic function
  • Abnormal renal function
  • History of alcohol or drug abuse within defined period, or current evidence of substance dependence or abuse
  • Participation in any other drug study within defined period
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Part 1: Low dose

    BID low dose of deucrictibant

    Drug: Deucrictibant low dose

  • Experimental
    Part 1: High dose

    BID high dose of deucrictibant

    Drug: Deucrictibant high dose

  • Placebo comparator
    Part 1: Placebo

    BID placebo

    Drug: Placebo

  • Experimental
    Part 2: Open-label

    BID high dose of deucrictibant

    Drug: Deucrictibant high dose

Interventions

  • DrugDeucrictibant low dose

    Deucrictibant softgel capsules for oral use (PHVS416)

  • DrugDeucrictibant high dose

    Deucrictibant softgel capsules for oral use (PHVS416)

  • DrugPlacebo

    Matching placebo capsules for oral use

06

What researchers measure

Primary outcomes

  1. Number of Investigator-confirmed Hereditary Angioedema (HAE) Attacks (Expressed as the Normalized Number of Attacks Per Month [4 Weeks] of Exposure) During the Treatment Period in Part 1

    HAE attack was defined as signs or symptoms in ≥1 location: peripheral angioedema (cutaneous swelling involving an extremity, face, neck, torso, and/or genitourinary region), abdominal angioedema (abdominal pain with or without abdominal distension, nausea, vomiting, or diarrhea), or upper airway angioedema (lump sensation, difficulty swallowing, throat tightening, difficulty speaking, hoarseness, stridor, dyspnea, or swelling of tongue, palate, uvula, or larynx). A new attack was counted if symptoms occurred ≥24 hours after complete resolution of a prior attack. Attacks were recorded via daily electronic patient-reported outcome (ePRO) diaries and confirmed by the investigator. Monthly attack rate was calculated as number of attacks during treatment divided by treatment days, multiplied by 28. Mean rate ratio, confidence interval (CI), and p-value were estimated using a generalized linear model with Poisson distribution, with baseline attack rate included as a factor.

    Time frame: Up to Day 84

Secondary outcomes

  1. Number of Investigator-confirmed Moderate or Severe HAE Attacks During the Treatment Period in Part 1

    HAE attack was defined as signs or symptoms in ≥1 location: peripheral angioedema (cutaneous swelling involving an extremity, face, neck, torso, and/or genitourinary region), abdominal angioedema (abdominal pain with or without abdominal distension, nausea, vomiting, or diarrhea), or upper airway angioedema (lump sensation, difficulty swallowing, throat tightening, difficulty speaking, hoarseness, stridor, dyspnea, or swelling of tongue, palate, uvula, or larynx). A new attack was counted if symptoms occurred ≥24 hours after complete resolution of a prior attack. Attacks were recorded via daily ePRO diaries and confirmed by the investigator. Monthly attack rate was calculated as number of attacks during treatment divided by treatment days×28. Moderate HAE attack defined as which limits/interferes with the participant's ability to attend work/school or participate in family life and social/recreational activities whereas Severe HAE attack significantly limits the participant's ability.

    Time frame: Up to Day 84

  2. Number of Investigator-confirmed HAE Attacks Requiring Acute Treatment During the Treatment Period in Part 1

    HAE attack was defined as signs or symptoms in ≥1 location: peripheral angioedema (cutaneous swelling involving an extremity, face, neck, torso, and/or genitourinary region), abdominal angioedema (abdominal pain with or without abdominal distension, nausea, vomiting, or diarrhea), or upper airway angioedema (lump sensation, difficulty swallowing, throat tightening, difficulty speaking, hoarseness, stridor, dyspnea, or swelling of tongue, palate, uvula, or larynx). A new attack was counted if symptoms occurred ≥24 hours after complete resolution of a prior attack. Attacks were recorded via daily ePRO diaries and confirmed by the investigator. Monthly attack rate was calculated as number of attacks during treatment divided by treatment days, multiplied by 28.

    Time frame: Up to Day 84

  3. Number of Participants Achieving ≥50%, ≥70% and ≥90% Reduction in Attack Rate Relative to Baseline During the Treatment Period in Part 1

    Baseline attack rate was defined as each participant's normalized HAE attack rate (attacks per 4 weeks) prior to randomization, based on documented history or confirmed during screening. Monthly attack rate was calculated as number of attacks during treatment divided by treatment days, multiplied by 28. Percent reduction from baseline was calculated for each participant by comparing the normalized treatment-period attack rate to the baseline attack rate. Participants were classified as responders if they achieved ≥50%, ≥70%, or ≥90% reduction in attack rate relative to baseline during Part 1.

    Time frame: Up to Day 84

  4. Number of Participants Who Were Investigator-confirmed Attack-free During the Treatment Period in Part 1

    HAE attack was defined as signs or symptoms in ≥1 location: peripheral angioedema (cutaneous swelling involving an extremity, face, neck, torso, and/or genitourinary region), abdominal angioedema (abdominal pain with or without abdominal distension, nausea, vomiting, or diarrhea), or upper airway angioedema (lump sensation, difficulty swallowing, throat tightening, difficulty speaking, hoarseness, stridor, dyspnea, or swelling of tongue, palate, uvula, or larynx). A new attack was counted if symptoms occurred ≥24 hours after complete resolution of a prior attack. Attacks were recorded via daily ePRO diaries and confirmed by the investigator. Participants reporting no confirmed attacks over the treatment period were considered attack-free.

    Time frame: Up to Day 84

  5. Number of Days With Investigator-confirmed HAE Symptoms During the Treatment Period in Part 1

    HAE attack was defined as signs or symptoms in ≥1 location: peripheral angioedema (cutaneous swelling involving an extremity, face, neck, torso, and/or genitourinary region), abdominal angioedema (abdominal pain with or without abdominal distension, nausea, vomiting, or diarrhea), or upper airway angioedema (lump sensation, difficulty swallowing, throat tightening, difficulty speaking, hoarseness, stridor, dyspnea, or swelling of tongue, palate, uvula, or larynx). HAE symptom days were identified from daily participant entries in the ePRO diary and were confirmed by the investigator.

    Time frame: Up to Day 84

  6. Proportion of Days With Investigator-confirmed HAE Symptoms During the Treatment Period in Part 1

    HAE attack was defined as signs or symptoms in ≥1 location: peripheral angioedema (cutaneous swelling involving an extremity, face, neck, torso, and/or genitourinary region), abdominal angioedema (abdominal pain with or without abdominal distension, nausea, vomiting, or diarrhea), or upper airway angioedema (lump sensation, difficulty swallowing, throat tightening, difficulty speaking, hoarseness, stridor, dyspnea, or swelling of tongue, palate, uvula, or larynx). HAE symptom days were identified from daily participant entries in the ePRO diary and were confirmed by the investigator.

    Time frame: Up to Day 84

  7. Time to First Investigator-confirmed HAE Attack in the Treatment Period in Part 1

    Time to first investigator-confirmed HAE attack was defined as days from date of first administration of study drug until the onset date of first Investigator-confirmed HAE attack. Participants without an Investigator-confirmed HAE attack during the treatment period in Part 1 were censored at the date of the last dose of study drug +1 in Part 1 or last day of the study, whichever came sooner.

    Time frame: Up to Day 84

  8. Number of Investigator-confirmed HAE Attacks Resulting in a Visit to the Emergency Department or an Admission to Hospital During the Treatment Period in Part 1

    HAE attack was defined as signs or symptoms in ≥1 location: peripheral angioedema (cutaneous swelling involving an extremity, face, neck, torso, and/or genitourinary region), abdominal angioedema (abdominal pain with or without abdominal distension, nausea, vomiting, or diarrhea), or upper airway angioedema (lump sensation, difficulty swallowing, throat tightening, difficulty speaking, hoarseness, stridor, dyspnea, or swelling of tongue, palate, uvula, or larynx). A new attack was counted if symptoms occurred ≥24 hours after complete resolution of a prior attack. Attacks were recorded via daily ePRO diaries and confirmed by the investigator. Monthly attack rate was calculated as number of attacks during treatment divided by treatment days, multiplied by 28. Only Investigator-confirmed attacks resulting in emergency department visits or hospital admissions were included.

    Time frame: Up to Day 84

  9. Number of Investigator-confirmed HAE Attacks During the Treatment Period in Part 2

    HAE attack was defined as signs or symptoms in ≥1 location: peripheral angioedema (cutaneous swelling involving an extremity, face, neck, torso, and/or genitourinary region), abdominal angioedema (abdominal pain with or without abdominal distension, nausea, vomiting, or diarrhea), or upper airway angioedema (lump sensation, difficulty swallowing, throat tightening, difficulty speaking, hoarseness, stridor, dyspnea, or swelling of tongue, palate, uvula, or larynx). A new attack was counted if symptoms occurred ≥24 hours after complete resolution of a prior attack. Attacks were recorded via daily ePRO diaries and confirmed by the investigator. Monthly attack rate was calculated as number of attacks during treatment divided by treatment days, multiplied by 28. An attack will be counted as in Part 2 if it occurs after the first IMP administration in Part 2 and within 24 hours after last IMP administration in Part 2.

    Time frame: Day 84 to Day 938

  10. Number of Investigator-confirmed Moderate or Severe HAE Attacks During the Treatment Period in Part 2

    HAE attack was defined as signs or symptoms in ≥1 location: peripheral angioedema (cutaneous swelling involving an extremity, face, neck, torso, and/or genitourinary region), abdominal angioedema (abdominal pain with or without abdominal distension, nausea, vomiting, or diarrhea), or upper airway angioedema (lump sensation, difficulty swallowing, throat tightening, difficulty speaking, hoarseness, stridor, dyspnea, or swelling of tongue, palate, uvula, or larynx). Attacks were recorded via daily ePRO diaries and confirmed by the investigator. Monthly attack rate was calculated as number of attacks during treatment divided by treatment days×28. Moderate HAE attack defined as which limits/interferes with the participant's ability to attend work/school or participate in family life and social/recreational activities whereas Severe HAE attack significantly limits the participant's ability. LSM and SE were estimated using a generalized linear model with Poisson distribution.

    Time frame: Day 84 to Day 938

  11. Number of Investigator-confirmed HAE Attacks Requiring Acute Treatment During the Treatment Period in Part 2

    HAE attack was defined as signs or symptoms in ≥1 location: peripheral angioedema (cutaneous swelling involving an extremity, face, neck, torso, and/or genitourinary region), abdominal angioedema (abdominal pain with or without abdominal distension, nausea, vomiting, or diarrhea), or upper airway angioedema (lump sensation, difficulty swallowing, throat tightening, difficulty speaking, hoarseness, stridor, dyspnea, or swelling of tongue, palate, uvula, or larynx). A new attack was counted if symptoms occurred ≥24 hours after complete resolution of a prior attack. Attacks were recorded via daily ePRO diaries and confirmed by the investigator. Monthly attack rate was calculated as number of attacks during treatment divided by treatment days, multiplied by 28. LSM and SE were estimated using a generalized linear model with Poisson distribution.

    Time frame: Day 84 to Day 938

  12. Number of Days With Investigator-confirmed HAE Symptoms During the Treatment Period in Part 2

    HAE attack was defined as signs or symptoms in ≥1 location: peripheral angioedema (cutaneous swelling involving an extremity, face, neck, torso, and/or genitourinary region), abdominal angioedema (abdominal pain with or without abdominal distension, nausea, vomiting, or diarrhea), or upper airway angioedema (lump sensation, difficulty swallowing, throat tightening, difficulty speaking, hoarseness, stridor, dyspnea, or swelling of tongue, palate, uvula, or larynx). HAE symptom days were identified from daily participant entries in the ePRO diary and were confirmed by the investigator.

    Time frame: Day 84 to Day 938

  13. Proportion of Days With Investigator-confirmed HAE Symptoms During the Treatment Period in Part 2

    HAE attack was defined as signs or symptoms in ≥1 location: peripheral angioedema (cutaneous swelling involving an extremity, face, neck, torso, and/or genitourinary region), abdominal angioedema (abdominal pain with or without abdominal distension, nausea, vomiting, or diarrhea), or upper airway angioedema (lump sensation, difficulty swallowing, throat tightening, difficulty speaking, hoarseness, stridor, dyspnea, or swelling of tongue, palate, uvula, or larynx). HAE symptom days were identified from daily participant entries in the ePRO diary and were confirmed by the investigator.

    Time frame: Day 84 to Day 938

07

Results

Posted Aug 17, 2026

Participant flow

A total of 34 participants were enrolled and randomized to receive placebo, deucrictibant 10 mg BID, or deucrictibant 20 mg BID in Part 1 (Double-blind Treatment Period). Participants who completed Part 1 were eligible to continue in Part 2 (Open-label Treatment Period) and were assigned to receive to receive deucrictibant 20 mg BID.

Part 1: Double-blind (Day 0 to 84)
Participant flow — Part 1: Double-blind (Day 0 to 84)
MilestonePart 1: PlaceboPart 1: Deucrictibant 10 mg BIDPart 1: Deucrictibant 20 mg BIDPart 2: Deucrictibant 20 mg BID
Started1111120
Completed911100
Not completed2020
Withdrew: Lost to follow-up1000
Withdrew: Withdrawal by subject1010
Withdrew: Study paused by sponsor/fda0010
Part 2: Open-label (Day 84 to Day 938)
Participant flow — Part 2: Open-label (Day 84 to Day 938)
MilestonePart 1: PlaceboPart 1: Deucrictibant 10 mg BIDPart 1: Deucrictibant 20 mg BIDPart 2: Deucrictibant 20 mg BID
Started00030
Completed0000
Not completed00030
Withdrew: Lost to follow-up0001
Withdrew: Pregnancy0001
Withdrew: Study terminated by sponsor0002
Withdrew: Withdrawal by subject0003
Withdrew: Study paused by sponsor/fda0002
Withdrew: Rolled over from part 2 to study pha022121-c307 (nct06679881)00021

Outcome measures

PrimaryNumber of Investigator-confirmed Hereditary Angioedema (HAE) Attacks (Expressed as the Normalized Number of Attacks Per Month [4 Weeks] of Exposure) During the Treatment Period in Part 1

HAE attack was defined as signs or symptoms in ≥1 location: peripheral angioedema (cutaneous swelling involving an extremity, face, neck, torso, and/or genitourinary region), abdominal angioedema (abdominal pain with or without abdominal distension, nausea, vomiting, or diarrhea), or upper airway angioedema (lump sensation, difficulty swallowing, throat tightening, difficulty speaking, hoarseness, stridor, dyspnea, or swelling of tongue, palate, uvula, or larynx). A new attack was counted if symptoms occurred ≥24 hours after complete resolution of a prior attack. Attacks were recorded via daily electronic patient-reported outcome (ePRO) diaries and confirmed by the investigator. Monthly attack rate was calculated as number of attacks during treatment divided by treatment days, multiplied by 28. Mean rate ratio, confidence interval (CI), and p-value were estimated using a generalized linear model with Poisson distribution, with baseline attack rate included as a factor.

Time frame:
Up to Day 84
Reported as:
Least squares mean · attacks per month
Number of Investigator-confirmed Hereditary Angioedema (HAE) Attacks (Expressed as the Normalized Number of Attacks Per Month [4 Weeks] of Exposure) During the Treatment Period in Part 1
attacks per monthPlaceboDeucrictibant 10 mg BIDDeucrictibant 20 mg BID
Number of Investigator-confirmed Hereditary Angioedema (HAE) Attacks (Expressed as the Normalized Number of Attacks Per Month [4 Weeks] of Exposure) During the Treatment Period in Part 11.93 ± 0.3910.40 ± 0.1700.30 ± 0.153
Statistical analysis
  • Placebo vs Deucrictibant 10 mg BID · Poisson Regression Model · p = 0.0010 · Percent reduction: 79.24 · 95% CI 47.23 to 91.83The percent reduction in attack rates as compared to placebo along with its 95% CI was calculated based on the estimated rate ratios as (1 minus mean rate ratio) multiplied by 100% for each of the deucrictibant dose group respectively.
  • Placebo vs Deucrictibant 20 mg BID · Poisson Regression Model · p = 0.0008 · Percent reduction: 84.46 · 95% CI 53.83 to 94.77The percent reduction in attack rates as compared to placebo along with its 95% CI was calculated based on the estimated rate ratios as (1 minus mean rate ratio) multiplied by 100% for each of the deucrictibant dose group respectively.
SecondaryNumber of Investigator-confirmed Moderate or Severe HAE Attacks During the Treatment Period in Part 1

HAE attack was defined as signs or symptoms in ≥1 location: peripheral angioedema (cutaneous swelling involving an extremity, face, neck, torso, and/or genitourinary region), abdominal angioedema (abdominal pain with or without abdominal distension, nausea, vomiting, or diarrhea), or upper airway angioedema (lump sensation, difficulty swallowing, throat tightening, difficulty speaking, hoarseness, stridor, dyspnea, or swelling of tongue, palate, uvula, or larynx). A new attack was counted if symptoms occurred ≥24 hours after complete resolution of a prior attack. Attacks were recorded via daily ePRO diaries and confirmed by the investigator. Monthly attack rate was calculated as number of attacks during treatment divided by treatment days×28. Moderate HAE attack defined as which limits/interferes with the participant's ability to attend work/school or participate in family life and social/recreational activities whereas Severe HAE attack significantly limits the participant's ability.

Time frame:
Up to Day 84
Reported as:
Least squares mean · attacks per month
Number of Investigator-confirmed Moderate or Severe HAE Attacks During the Treatment Period in Part 1
attacks per monthPlaceboDeucrictibant 10 mg BIDDeucrictibant 20 mg BID
Number of Investigator-confirmed Moderate or Severe HAE Attacks During the Treatment Period in Part 11.51 ± 0.3940.26 ± 0.1500.12 ± 0.103
SecondaryNumber of Investigator-confirmed HAE Attacks Requiring Acute Treatment During the Treatment Period in Part 1

HAE attack was defined as signs or symptoms in ≥1 location: peripheral angioedema (cutaneous swelling involving an extremity, face, neck, torso, and/or genitourinary region), abdominal angioedema (abdominal pain with or without abdominal distension, nausea, vomiting, or diarrhea), or upper airway angioedema (lump sensation, difficulty swallowing, throat tightening, difficulty speaking, hoarseness, stridor, dyspnea, or swelling of tongue, palate, uvula, or larynx). A new attack was counted if symptoms occurred ≥24 hours after complete resolution of a prior attack. Attacks were recorded via daily ePRO diaries and confirmed by the investigator. Monthly attack rate was calculated as number of attacks during treatment divided by treatment days, multiplied by 28.

Time frame:
Up to Day 84
Reported as:
Least squares mean · attacks per month
Number of Investigator-confirmed HAE Attacks Requiring Acute Treatment During the Treatment Period in Part 1
attacks per monthPlaceboDeucrictibant 10 mg BIDDeucrictibant 20 mg BID
Number of Investigator-confirmed HAE Attacks Requiring Acute Treatment During the Treatment Period in Part 11.40 ± 0.3370.35 ± 0.1590.10 ± 0.089
SecondaryNumber of Participants Achieving ≥50%, ≥70% and ≥90% Reduction in Attack Rate Relative to Baseline During the Treatment Period in Part 1

Baseline attack rate was defined as each participant's normalized HAE attack rate (attacks per 4 weeks) prior to randomization, based on documented history or confirmed during screening. Monthly attack rate was calculated as number of attacks during treatment divided by treatment days, multiplied by 28. Percent reduction from baseline was calculated for each participant by comparing the normalized treatment-period attack rate to the baseline attack rate. Participants were classified as responders if they achieved ≥50%, ≥70%, or ≥90% reduction in attack rate relative to baseline during Part 1.

Time frame:
Up to Day 84
Reported as:
Count of participants · Participants
Number of Participants Achieving ≥50%, ≥70% and ≥90% Reduction in Attack Rate Relative to Baseline During the Treatment Period in Part 1
ParticipantsPlaceboDeucrictibant 10 mg BIDDeucrictibant 20 mg BID
≥50% reduction299
≥70% reduction298
≥90% reduction066
SecondaryNumber of Participants Who Were Investigator-confirmed Attack-free During the Treatment Period in Part 1

HAE attack was defined as signs or symptoms in ≥1 location: peripheral angioedema (cutaneous swelling involving an extremity, face, neck, torso, and/or genitourinary region), abdominal angioedema (abdominal pain with or without abdominal distension, nausea, vomiting, or diarrhea), or upper airway angioedema (lump sensation, difficulty swallowing, throat tightening, difficulty speaking, hoarseness, stridor, dyspnea, or swelling of tongue, palate, uvula, or larynx). A new attack was counted if symptoms occurred ≥24 hours after complete resolution of a prior attack. Attacks were recorded via daily ePRO diaries and confirmed by the investigator. Participants reporting no confirmed attacks over the treatment period were considered attack-free.

Time frame:
Up to Day 84
Reported as:
Count of participants · Participants
Number of Participants Who Were Investigator-confirmed Attack-free During the Treatment Period in Part 1
ParticipantsPlaceboDeucrictibant 10 mg BIDDeucrictibant 20 mg BID
Number of Participants Who Were Investigator-confirmed Attack-free During the Treatment Period in Part 1064
SecondaryNumber of Days With Investigator-confirmed HAE Symptoms During the Treatment Period in Part 1

HAE attack was defined as signs or symptoms in ≥1 location: peripheral angioedema (cutaneous swelling involving an extremity, face, neck, torso, and/or genitourinary region), abdominal angioedema (abdominal pain with or without abdominal distension, nausea, vomiting, or diarrhea), or upper airway angioedema (lump sensation, difficulty swallowing, throat tightening, difficulty speaking, hoarseness, stridor, dyspnea, or swelling of tongue, palate, uvula, or larynx). HAE symptom days were identified from daily participant entries in the ePRO diary and were confirmed by the investigator.

Time frame:
Up to Day 84
Reported as:
Mean · days
Number of Days With Investigator-confirmed HAE Symptoms During the Treatment Period in Part 1
daysPlaceboDeucrictibant 10 mg BIDDeucrictibant 20 mg BID
Number of Days With Investigator-confirmed HAE Symptoms During the Treatment Period in Part 113.6 ± 9.693.8 ± 7.731.8 ± 2.25
SecondaryProportion of Days With Investigator-confirmed HAE Symptoms During the Treatment Period in Part 1

HAE attack was defined as signs or symptoms in ≥1 location: peripheral angioedema (cutaneous swelling involving an extremity, face, neck, torso, and/or genitourinary region), abdominal angioedema (abdominal pain with or without abdominal distension, nausea, vomiting, or diarrhea), or upper airway angioedema (lump sensation, difficulty swallowing, throat tightening, difficulty speaking, hoarseness, stridor, dyspnea, or swelling of tongue, palate, uvula, or larynx). HAE symptom days were identified from daily participant entries in the ePRO diary and were confirmed by the investigator.

Time frame:
Up to Day 84
Reported as:
Mean · proportion of days
Proportion of Days With Investigator-confirmed HAE Symptoms During the Treatment Period in Part 1
proportion of daysPlaceboDeucrictibant 10 mg BIDDeucrictibant 20 mg BID
Proportion of Days With Investigator-confirmed HAE Symptoms During the Treatment Period in Part 10.163 ± 0.11400.044 ± 0.08920.021 ± 0.0261
SecondaryTime to First Investigator-confirmed HAE Attack in the Treatment Period in Part 1

Time to first investigator-confirmed HAE attack was defined as days from date of first administration of study drug until the onset date of first Investigator-confirmed HAE attack. Participants without an Investigator-confirmed HAE attack during the treatment period in Part 1 were censored at the date of the last dose of study drug +1 in Part 1 or last day of the study, whichever came sooner.

Time frame:
Up to Day 84
Reported as:
Median · days
Time to First Investigator-confirmed HAE Attack in the Treatment Period in Part 1
daysPlaceboDeucrictibant 10 mg BIDDeucrictibant 20 mg BID
Time to First Investigator-confirmed HAE Attack in the Treatment Period in Part 19.0 (5.00 to 26.00)NA (19.00 to NA)86.0 (13.00 to NA)
SecondaryNumber of Investigator-confirmed HAE Attacks Resulting in a Visit to the Emergency Department or an Admission to Hospital During the Treatment Period in Part 1

HAE attack was defined as signs or symptoms in ≥1 location: peripheral angioedema (cutaneous swelling involving an extremity, face, neck, torso, and/or genitourinary region), abdominal angioedema (abdominal pain with or without abdominal distension, nausea, vomiting, or diarrhea), or upper airway angioedema (lump sensation, difficulty swallowing, throat tightening, difficulty speaking, hoarseness, stridor, dyspnea, or swelling of tongue, palate, uvula, or larynx). A new attack was counted if symptoms occurred ≥24 hours after complete resolution of a prior attack. Attacks were recorded via daily ePRO diaries and confirmed by the investigator. Monthly attack rate was calculated as number of attacks during treatment divided by treatment days, multiplied by 28. Only Investigator-confirmed attacks resulting in emergency department visits or hospital admissions were included.

Time frame:
Up to Day 84
Reported as:
Least squares mean · attacks per month
Number of Investigator-confirmed HAE Attacks Resulting in a Visit to the Emergency Department or an Admission to Hospital During the Treatment Period in Part 1
attacks per monthPlaceboDeucrictibant 10 mg BIDDeucrictibant 20 mg BID
Number of Investigator-confirmed HAE Attacks Resulting in a Visit to the Emergency Department or an Admission to Hospital During the Treatment Period in Part 10 ± 00 ± 00 ± 0
SecondaryNumber of Investigator-confirmed HAE Attacks During the Treatment Period in Part 2

HAE attack was defined as signs or symptoms in ≥1 location: peripheral angioedema (cutaneous swelling involving an extremity, face, neck, torso, and/or genitourinary region), abdominal angioedema (abdominal pain with or without abdominal distension, nausea, vomiting, or diarrhea), or upper airway angioedema (lump sensation, difficulty swallowing, throat tightening, difficulty speaking, hoarseness, stridor, dyspnea, or swelling of tongue, palate, uvula, or larynx). A new attack was counted if symptoms occurred ≥24 hours after complete resolution of a prior attack. Attacks were recorded via daily ePRO diaries and confirmed by the investigator. Monthly attack rate was calculated as number of attacks during treatment divided by treatment days, multiplied by 28. An attack will be counted as in Part 2 if it occurs after the first IMP administration in Part 2 and within 24 hours after last IMP administration in Part 2.

Time frame:
Day 84 to Day 938
Reported as:
Mean · attacks per month
Number of Investigator-confirmed HAE Attacks During the Treatment Period in Part 2
attacks per monthDeucrictibant 20 mg BID
Number of Investigator-confirmed HAE Attacks During the Treatment Period in Part 20.12 ± 0.224
SecondaryNumber of Investigator-confirmed Moderate or Severe HAE Attacks During the Treatment Period in Part 2

HAE attack was defined as signs or symptoms in ≥1 location: peripheral angioedema (cutaneous swelling involving an extremity, face, neck, torso, and/or genitourinary region), abdominal angioedema (abdominal pain with or without abdominal distension, nausea, vomiting, or diarrhea), or upper airway angioedema (lump sensation, difficulty swallowing, throat tightening, difficulty speaking, hoarseness, stridor, dyspnea, or swelling of tongue, palate, uvula, or larynx). Attacks were recorded via daily ePRO diaries and confirmed by the investigator. Monthly attack rate was calculated as number of attacks during treatment divided by treatment days×28. Moderate HAE attack defined as which limits/interferes with the participant's ability to attend work/school or participate in family life and social/recreational activities whereas Severe HAE attack significantly limits the participant's ability. LSM and SE were estimated using a generalized linear model with Poisson distribution.

Time frame:
Day 84 to Day 938
Reported as:
Least squares mean · attacks per month
Number of Investigator-confirmed Moderate or Severe HAE Attacks During the Treatment Period in Part 2
attacks per monthDeucrictibant 20 mg BID
Number of Investigator-confirmed Moderate or Severe HAE Attacks During the Treatment Period in Part 20.06 ± 0.024
SecondaryNumber of Investigator-confirmed HAE Attacks Requiring Acute Treatment During the Treatment Period in Part 2

HAE attack was defined as signs or symptoms in ≥1 location: peripheral angioedema (cutaneous swelling involving an extremity, face, neck, torso, and/or genitourinary region), abdominal angioedema (abdominal pain with or without abdominal distension, nausea, vomiting, or diarrhea), or upper airway angioedema (lump sensation, difficulty swallowing, throat tightening, difficulty speaking, hoarseness, stridor, dyspnea, or swelling of tongue, palate, uvula, or larynx). A new attack was counted if symptoms occurred ≥24 hours after complete resolution of a prior attack. Attacks were recorded via daily ePRO diaries and confirmed by the investigator. Monthly attack rate was calculated as number of attacks during treatment divided by treatment days, multiplied by 28. LSM and SE were estimated using a generalized linear model with Poisson distribution.

Time frame:
Day 84 to Day 938
Reported as:
Least squares mean · attacks per month
Number of Investigator-confirmed HAE Attacks Requiring Acute Treatment During the Treatment Period in Part 2
attacks per monthDeucrictibant 20 mg BID
Number of Investigator-confirmed HAE Attacks Requiring Acute Treatment During the Treatment Period in Part 20.06 ± 0.021
SecondaryNumber of Days With Investigator-confirmed HAE Symptoms During the Treatment Period in Part 2

HAE attack was defined as signs or symptoms in ≥1 location: peripheral angioedema (cutaneous swelling involving an extremity, face, neck, torso, and/or genitourinary region), abdominal angioedema (abdominal pain with or without abdominal distension, nausea, vomiting, or diarrhea), or upper airway angioedema (lump sensation, difficulty swallowing, throat tightening, difficulty speaking, hoarseness, stridor, dyspnea, or swelling of tongue, palate, uvula, or larynx). HAE symptom days were identified from daily participant entries in the ePRO diary and were confirmed by the investigator.

Time frame:
Day 84 to Day 938
Reported as:
Mean · days
Number of Days With Investigator-confirmed HAE Symptoms During the Treatment Period in Part 2
daysDeucrictibant 20 mg BID
Number of Days With Investigator-confirmed HAE Symptoms During the Treatment Period in Part 25.8 ± 12.05
SecondaryProportion of Days With Investigator-confirmed HAE Symptoms During the Treatment Period in Part 2

HAE attack was defined as signs or symptoms in ≥1 location: peripheral angioedema (cutaneous swelling involving an extremity, face, neck, torso, and/or genitourinary region), abdominal angioedema (abdominal pain with or without abdominal distension, nausea, vomiting, or diarrhea), or upper airway angioedema (lump sensation, difficulty swallowing, throat tightening, difficulty speaking, hoarseness, stridor, dyspnea, or swelling of tongue, palate, uvula, or larynx). HAE symptom days were identified from daily participant entries in the ePRO diary and were confirmed by the investigator.

Time frame:
Day 84 to Day 938
Reported as:
Mean · proportion of days
Proportion of Days With Investigator-confirmed HAE Symptoms During the Treatment Period in Part 2
proportion of daysDeucrictibant 20 mg BID
Proportion of Days With Investigator-confirmed HAE Symptoms During the Treatment Period in Part 20.009 ± 0.0173

Adverse events

Collected over Double-blind treatment period: Day 0 to 84 Open-label treatment period:Day 85 to Day 938. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Placebo0/11 (0%)0/11 (0%)7/11 (63.6%)
Part 1: Deucrictibant 10 mg BID0/11 (0%)0/11 (0%)6/11 (54.5%)
Part 1: Deucrictibant 20 mg BID0/12 (0%)0/12 (0%)7/12 (58.3%)
Part 2: Deucrictibant 20 mg BID0/30 (0%)2/30 (6.7%)24/30 (80%)
Most frequent serious events
Most frequent serious events
EventPart 1: PlaceboPart 1: Deucrictibant 10 mg BIDPart 1: Deucrictibant 20 mg BIDPart 2: Deucrictibant 20 mg BID
Tendon injuryInjury, poisoning and procedural complications0/110/110/121/30
ArthritisMusculoskeletal and connective tissue disorders0/110/110/121/30
OsteoarthritisMusculoskeletal and connective tissue disorders0/110/110/121/30
Most frequent other events
Showing 10 of 89
Most frequent other events
EventPart 1: PlaceboPart 1: Deucrictibant 10 mg BIDPart 1: Deucrictibant 20 mg BIDPart 2: Deucrictibant 20 mg BID
NasopharyngitisInfections and infestations1/112/110/1212/30
Abdominal pain upperGastrointestinal disorders2/110/110/121/30
Upper respiratory tract infectionInfections and infestations0/110/110/125/30
Abdominal painGastrointestinal disorders1/111/110/124/30
NauseaGastrointestinal disorders1/111/110/124/30
VomitingGastrointestinal disorders1/110/110/123/30
Urinary tract infectionInfections and infestations0/111/111/121/30
Gastrointestinal infectionInfections and infestations1/110/111/122/30
Viral pharyngitisInfections and infestations0/111/110/120/30
DiarrhoeaGastrointestinal disorders0/111/111/122/30

Baseline characteristics

Intent-to-Treat (ITT) Analysis Set comprised of all randomized participants who received at least one dose of the investigational medicinal product (IMP), deucrictibant or placebo.

Age, Continuous
Age, Continuous(years)PlaceboDeucrictibant 10 mg BIDDeucrictibant 20 mg BIDTotal
Mean41.4 ± 14.4538.4 ± 17.2440.8 ± 15.2140.2 ± 15.24
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboDeucrictibant 10 mg BIDDeucrictibant 20 mg BIDTotal
Female85821
Male36413
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboDeucrictibant 10 mg BIDDeucrictibant 20 mg BIDTotal
Hispanic or Latino0000
Not Hispanic or Latino11111133
Unknown or Not Reported0011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboDeucrictibant 10 mg BIDDeucrictibant 20 mg BIDTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White11111234
More than one race0000
Unknown or Not Reported0000
08

Study locations

19 sites
  • Study site
    Birmingham, Alabama 35209, United States
  • Study site
    Paradise Valley, Arizona 85253, United States
  • Study site
    St Louis, Missouri 63141, United States
  • Study Site
    Vienna, A-1090, Austria
  • Study site
    Sofia, 1680, Bulgaria
  • Study site
    Ottawa, Ontario K1H 1E4, Canada
  • Study site
    Montreal, Quebec H2W 1R7, Canada
  • Study site
    Berlin, 10117, Germany
  • Study site
    Frankfurt, 60323, Germany
  • Study site
    Dublin, D08NHY1, Ireland
  • Study site
    Padua, PD 35128, Italy
  • Study site
    Milan, 20157, Italy
  • Study site
    Palermo, 0146, Italy
  • Study site
    Krakow, Poland
  • Study site
    Brighton, England BN2 1ES, United Kingdom
  • Study site
    Bristol, England BS10 5NB, United Kingdom
  • Study site
    Cambridge, England CB2 0QQ, United Kingdom
  • Study site
    London, England E1 1FR, United Kingdom
  • Study site
    Southampton, England SO16 6YD, United Kingdom
09

References and documents

Publications

  • Aygoren-Pursun E, Stobiecki M, Valerieva A, Cancian M, Gompels M, Grigoriadou S, Kiani-Alikhan S, Kinaciyan T, Yang WH, Anderson J, Arcoleo F, Chapdelaine H, Conlon N, Eren E, Guarino MD, Gurugama P, Magerl M, Manning ME, Tarzi MD, Wedner HJ, Zanichelli A, Crabbe R, Mulders S, Levy J, Zhu L, Knolle J, Lesage A, Lu P, Riedl MA. Oral deucrictibant for prophylaxis of hereditary angioedema attacks (CHAPTER-1): primary analysis of a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Haematol. 2026 Apr;13(4):e215-e226. doi: 10.1016/S2352-3026(26)00004-9. Epub 2026 Mar 19. PubMed 41865746 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2022 to primary completion in Jun 2025, 38 months.

Results were first posted in Aug 2026, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2021
First posted
Sep 17, 2021
StartActual
Apr 19, 2022
Primary completionActual
Jun 30, 2025
CompletionActual
Jun 30, 2025
Results first posted
Aug 17, 2026
Last update
Aug 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05047185
Lead sponsor
Pharvaris Netherlands B.V.
Responsible party
Sponsor
First posted
Sep 17, 2021
Start date
Apr 19, 2022
Primary completion
Jun 30, 2025
Completion
Jun 30, 2025
Results posted
Aug 17, 2026
Last update
Aug 17, 2026

Study contacts

Marc Riedl, MD
principal investigator · UC San Diego, La Jolla, California, United States
Emel Aygören-Pürsün, MD
principal investigator · University Hospital Frankfurt - Goethe University, Frankfurt, Germany

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion